Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

ABSTRACT:

Background

Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors.

Methods

Adolescents, 12-18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociat

SUBMITTER: Cullen KR 

PROVIDER: S-EPMC6154760 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature